Akero Therapeutics, Inc. Investors: Class action lawsuit filed on behalf of investors; the Portnoy Law Firm
17 juin 2024 14h26 HE
|
Portnoy Law
Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, June 17, 2024 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Akero Therapeutics, Inc....
Akero Therapeutics, Inc. Investors: Class action lawsuit filed on behalf of investors; the Portnoy Law Firm
11 juin 2024 12h03 HE
|
Portnoy Law
Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, June 11, 2024 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Akero Therapeutics, Inc....
Akero Therapeutics, Inc. Investors: Class action lawsuit filed on behalf of investors; the Portnoy Law Firm
06 juin 2024 14h28 HE
|
Portnoy Law
Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, June 06, 2024 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Akero Therapeutics, Inc....
AKRO STOCKHOLDERS - Contact Robbins LLP for Information About the Pending Lead Plaintiff Deadline in the Akero Therapeutics, Inc. Class Action
05 juin 2024 16h18 HE
|
Robbins LLP
Robbins LLP is Investigating Allegations that Akero Therapeutics, Inc. (AKRO) Misled Investors Regarding the Viability of its Trial Drug Candidate
Robbins LLP Reminds Investors of AKRO of the Pending Lead Plaintiff Deadline in the Akero Therapeutics, Inc. Class Action
16 mai 2024 16h15 HE
|
Robbins LLP
Robbins LLP is Investigating Allegations that Akero Therapeutics, Inc. (AKRO) Misled Investors Regarding the Viability and Efficacy of its Trial Drug Candi
AKRO Class Action Alert: Robbins LLP Reminds Investors of the Lead Plaintiff Deadline in the Class Action Against Akero Therapeutics, Inc.
07 mai 2024 15h06 HE
|
Robbins LLP
Robbins LLP is Investigating Allegations that Akero Therapeutics, Inc. (AKRO) Misled Investors Regarding the Viability and Efficacy of its Trial Drug Candi
Stockholder Alert: Robbins LLP Informs Investors of the Class Action Filed Against Akero Therapeutics, Inc. (AKRO)
30 avr. 2024 00h42 HE
|
Robbins LLP
Robbins LLP is Investigating Allegations that Akero Therapeutics, Inc. (AKRO) Misled Investors Regarding the Viability and Efficacy of its Trial Drug Candi